{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:hydralazine",
  "owner": "cardio",
  "kind": "drug",
  "slug": "hydralazine",
  "name": "Hydralazine",
  "aliases": [
    "Hydralazine hydrochloride"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Hydralazine is a direct vasodilator, a medicine taken by mouth that the label says apparently lowers blood pressure by relaxing the muscle in blood vessel walls. The US label read, for generic hydralazine hydrochloride tablets, lists essential hypertension, alone or as an adjunct (an add-on to other treatment). The label says the precise mechanism of action is not fully understood.",
  "summary_technical": "RxNorm ingredient 5470 (hydralazine hydrochloride is 82027); UNII FD171B778Y is the UNII of the hydrochloride salt that the label gives, so it is a broad match. MeSH descriptor D006830 is Hydralazine. RxClass lists the FDA established pharmacologic class Arteriolar Vasodilator, the class the direct vasodilators page records for minoxidil; the record is filed under that page on that evidence, and the page gained the alias Arteriolar vasodilator for it. The label read is the Chartwell RX, LLC generic tablet label, application ANDA086242, effective 2025-12-10 in openFDA, the label the class page already uses. The UNII and application number come from the openFDA record as read on 2026-11-09; the record read again on 2026-11-18 has the same effective date but no longer carries those fields. The plan row's label (set id 024ac6b8) was not read, and the combination products that contain hydralazine were not read. This page records the label indication and the mechanism sentences only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "5470",
      "normalized_value": "5470",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "FD171B778Y",
      "normalized_value": "FD171B778Y",
      "match": "broad",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D006830",
      "normalized_value": "D006830",
      "match": "exact",
      "version": "read 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels"
      ],
      "condition-area": [
        "hypertension"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says the precise mechanism of action is not fully understood and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle."
  },
  "content_digest": "a720f56047a97697bf4062548a20b76ce78b6557d6c413051cbce1013ae25590",
  "review": {
    "content_digest": "a720f56047a97697bf4062548a20b76ce78b6557d6c413051cbce1013ae25590",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-hydralazine-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:hydralazine",
      "category": "descriptive",
      "statement": "The US label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct. It says the precise mechanism of action is not fully understood, and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.",
      "context": {
        "id": "cardio:ctx-fda-hydralazine-label-us",
        "label": "People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets",
        "recipient": "unknown",
        "population": "Patients with essential hypertension, as the indications section of the label states. The label passages read do not state an age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the label passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with essential hypertension"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and the combination products that contain hydralazine were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read.",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read.",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0]",
          "applicability_note": "Label passage quoted in the research quote table (HYD-LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].clinical_pharmacology[0]",
          "applicability_note": "Label passage quoted in the research quote table (HYD-LB-05, HYD-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-hydralazine-chartwell-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:45Z",
            "content_hash": "4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0",
            "source_effective_date": "2025-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-hydralazine-chartwell",
            "source_type": "regulator",
            "title": "openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%220c7f9bd0-6c0a-4521-b77a-3582faa96874%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-hydralazine-chartwell.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "1c142e9823b93870452487717a3265976bc8f8b98a4c03e0a59c31b5ac94a3cd",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-hydralazine-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Hydralazine is an arteriolar vasodilator (FDA established pharmacologic class in RxClass), the class the direct vasodilators page records",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:direct-vasodilators-hydralazine-minoxidil",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-5470-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists essential hypertension, alone or as an adjunct, as the indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "core:hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-hydralazine-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/hydralazine/",
  "context_path": "api/v1/context/cardio--hydralazine.md"
}
